DSGN Stock Price Quote

Table Of Content

• Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
• Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
• Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
• Design Therapeutics (DSGN) Earnings Date, Estimates & Call Transcripts
• Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

This makes it difficult to properly value the company and its stock, as Design Therapeutics has no price-to-earnings (P/E) ratio since it has no earnings. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia, a ge... Yes, I think it's an issue for all doses.

Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track

Design’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com. Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. Design Therapeutics last released its earnings data on March 19th, 2024. The reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.11.

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

The biotech company released phase 1 trial details regarding a Friedreich ataxia therapy. © 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer. The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

And I think probably six months or nine months would be the two most likely candidates for duration of the Phase IIb. Shares of Design Therapeutics stock traded down $0.01 during trading on Wednesday, hitting $3.65. The stock had a trading volume of 192,880 shares, compared to its average volume of 262,557. The stock has a market cap of $206.19 million, a PE ratio of -3.04 and a beta of 1.82.

DT-216 Safely Doubles FXN Gene Activity in FA in Phase 1 Trial ... - Friedreich's Ataxia News

DT-216 Safely Doubles FXN Gene Activity in FA in Phase 1 Trial ....

Posted: Tue, 13 Dec 2022 08:00:00 GMT [source]

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nisa Investment Advisors LLC increased its stake in shares of Design Therapeutics by 38,433.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 11,560 shares of the company's stock worth $31,000 after purchasing an additional 11,530 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Design Therapeutics in the third quarter worth $47,000.

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs - PR Newswire

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs.

Posted: Tue, 02 Apr 2024 07:00:00 GMT [source]

That’s fine, but it doesn’t mean Design Therapeutics will deliver strong value to its shareholders this year. One can certainly root for Design Therapeutics and support the company’s potentially lifesaving research. Investing in the company is a different story entirely, though, and I simply can’t recommend it. And so we would expect a ruling on the dispute sometime this quarter, but it's hard to speculate since it's a ongoing litigation.

Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?

Since we're talking about the upcoming discussion with the FDA. I'm just curious if you have any lingering questions or actually items you'd like to discuss with the agency around midyear. Phase IIb study, yes, we're going to have a Type C meeting with the FDA later this quarter.

Design Therapeutics (DSGN) Earnings Date, Estimates & Call Transcripts

In addition, the company’s cash, cash equivalents and investment securities declined from $384.1 million at the end of 2021 to $330.4 million at the end of 2022. The first red flag here is the price action of DSGN stock. It’s the same story that you may have seen with other high-risk biotech stocks. The Design Therapeutics share price has fallen from around $30 in 2021 to just $5 and change recently. According to 4 analysts, the average rating for DSGN stock is "Hold." The 12-month stock price forecast is $5.0, which is an increase of 32.28% from the latest price. We are advancing a pipeline of novel candidates with an initial focus on monogenic repeat expansion disorders with urgent medical need, including Friedreich ataxia, Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy.

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Thanks for taking the questions and congrats on the progress. Brian, you just mentioned for the VOYAGE study for fibrosis. You mentioned that there might be a few patients here. And can you just remind us if the study is powered to show a difference in fibrosis in the study and have a follow-up. Well, I think more data is always helpful to potential partners, but we don't view it as a gating for us to have meaningful conversations. And I'm not sure it's necessarily gating for others to have meaningful conversations with us.

But and generally, the larger partners like to see more data as programs evolve. But again, that's not a I don't think that's a mandatory requirement right now. Oh, hey, congrats on all the progress and thank you for providing this update for subcu VK. What kind of data should we expect in 2Q?

You can view a copy of the complaint by clicking here. So we have previously shown with that compound somewhere in the in the 20% range on LDL reduction and in the 20% range for APOB. So we know it's effective at lipid reduction and we also looked very long-chain fatty acids in the healthy volunteers. That's kind of tough to look because they're there healthy volunteers.

We are getting a lot of questions around that given the supply problems that current manufacturers have with their own therapies right now. So I just wanted to know if you're going into this on with that thought in mind. And on the second is, I guess, given some of the additional benefits that we lost drugs are having, whether it's on CV risk or hypertension or kidney disease and sleep apnea?